10/590427 IAP9 Rec'd PCT/PTO 23 AUG 2006

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sheet	1		of	3			Attorne	y Docket Ni	ımber	2578-7	869US	
						U.S. PAT	ENT D	OCUME	NTS			
Examiner Initials *	Cite No.1		Document Number Number - Kind Code ² (if known) US-5,559,099			Publication MM-DD-Y	Date	Name of	ame of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant	
	_	US-5,559				09-24-19	196	V	Vickham et al.		Figures Appear	
		US- 5,78				08-04-19		Descamps et al. Falck-Pedersen et al.				
		US- 5,83				11-17-19	98					
		US- 5,83	7,520			11-17-19	98					
		US- 5,84	0,565			11-24-19	98	1	Lau			
		US- 5,84	6,782			12-08-19	98	V	Vickham et al.			
		US- 5,85	1,806		- "	12-22-19	98		Kovesdi et al.			
		US- 5,89	1,690			04-06-19	99		Massie			
		US- 5,94	18,410			09-07-19	99	Van 9	Scharrenburg e	et al.		
		US- 5,96	US- 5,965,541			10-12-19	99	Wickham et al.				
		US- 5,98	31,225			11-09-19	99	Kochanek et al.				
		US- 5,994,106			11-30-19	999	Kovesdi et al.					
		US- 5,99	4,128			11-30-19	99		Fallaux et al.			
		US- 5,99	US- 5,994,134			11-30-1999		Giroux et al.				
		US- 6,00	US- 6,008,036		12-28-1999		Fanget et al.					
		US- 6,02	US- 6,020,191			02-01-20	000	Scaria et al.				
	US- 6,040,174		03-21-20	000	Imler et al.							
		US- 6,11	13,913			09-05-20	09-05-2000 Brough et al.		Brough et al.			
		US- 6,14	6,873			11-14-20	000	<u> </u>	Kistner et al.			
		US- 6,168,941			01-02-20	001	O1 Liu					
						FOREIC	GN PA	TENT D	OCUMENT	`S		
Examiner Initials*	Cite Foreign Patent Docu No. 1 Country Code ³ - Number ⁴ - Kind Co				cation Date	Name of Pat Applicant of Docum	f Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶			
			··· · · ·		30 354 B		08-	14-2002	Ceve Pharmace Gmb	uticals	roovan riginos appear	
•				WO 9	9/41416		08-	19-1999	Schering	Corp.		
				WO 9	9/12568		03-	18-1999	Merck & C	o., Inc.		
				WO 9	8/39411		09-	11-1998	Baxter Int'l, Inc.			
			WO 98/22588			3		28-1998	Introg Therapeut			
				WO 9	7/08298	3	03-	06-1997	Genzyme	Corp.		
				WO 9	6/26281		08-	29-1996	Genvec, In	c. et al.		
				WO 03	3/084479	9	10-	16-2003	Merck & C	o., Inc.		
				WO 03	3/097797	7	11-	27-2003	Merck & C	o., Inc.		

	. yana a <u></u>	_	
Examiner		Date	
Signature		Considered	<u> </u>

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

10/590427 IAP9 Rec'd PCT/PTO 23 AUG 2006

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

2. OMB 0651-0031
OF COMMERCE

Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE Application Number To be assigned Filing Date August 23, 2006 STATEMENT BY APPLICANT First Named Inventor Weggeman et al Group Art Unit To be assigned (use as many sheets as necessary) **Examiner Name** To be assigned 2578-7869US Sheet Attorney Docket Number

Sheet	<u> </u>	01 3		Attorne	y Docket N	umber 25/8-/	86908	
			U.S. PATE	ENT D	OCUME	ENTS		
Examiner Cite Initials • No.		Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US - 6,168,944	01-02-2001		Condon et al.			
-		US - 6,261,823	07-17-2001			Tang et al.		
		US - 6,309,650	10-30-200	Nim et al.		Kim et al.		
	1	US - 6,342,384	01-29-200	02	Chung et al.			
		US - 6,485,958	11-26-200			Blanche et al.		
	<u> </u>	US - 6,492,169	12-10-200			Vogels et al.		
	 	US - 6,537,793	03-25-200	03	Carrion et al.			-
		US - 6,586,226	07-01-200	03				
		US - 2002/182723	12-05-200	02				
	'		FOREIG	N PA	TENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Doc Country Code ³ - Number ⁴ - Kind C	ument	nt Publication Dat		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ ⁶
		WO 03/10446	12-		18-2003	Crucell Holland B.V.		
		WO 2004/0010	32	12-	31-2003	Crucell Holland B.V.		
		WO 03/07859	2	09-	25-2003	Cell Genesys, Inc.		
		WO 03/02863	2 04		10-2003	Government of the U.S.A., as represented by the Secretary, Dept. of H. H. S.		
		WO 03/04976	3 06-		19-2003	Mayne Pharma PTY LTD		
		WO 02/07067			12-2002	Schering Aktiengesellschaft		<u> </u>
	ļ	WO 02/4434			06-2002	Schering Corp.	<u></u>	ļ
	ļ	WO 01/7730		10-1		Genvec, Inc.		ļ
	<u> </u>	WO 02/2208			21-2002	Merck & Co., Inc.	ļ	
		WO 00/5057			31-2000	Transgene S.A.		<u> </u>
		WO 00/0302			20-2000	Introgene B.V.		<u> </u>
	<u> </u>	WO 2005/0805	556		01-2005	Crucell Holland B.V.		1
		WO 00/7007	1	11-	23-2000	Introgene B.V.		ļ
		WO 01/3836	2	05-	31-2001	Crucell Holland B.V.		<u> </u>
				-				ļ

		$\overline{}$
Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional) . 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

10/590427 IAP9 Rec'd PCT/PTO 23 AUG 2006

PTO.	/SB/08B	(10-01)
------	---------	---------

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known To be assigned Application Number INFORMATION DISCLOSURE Filing Date August 23, 2006 STATEMENT BY APPLICANT First Named Inventor Weggeman et al. Group Art Unit To be assigned (use as many sheets as necessary) **Examiner Name** To be assigned Sheet of 3 Attorney Docket Number 2578-7869US

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	!	PCT International Preliminary Report on Patentability, PCT/ EP2005/050439, dated July 18, 2006.				
		PCT International Search Report, PCT/EP 2005/050439, dated October 27, 2005.				
•		GREEN et al., "A new Scalable Method for the Purification of Recombinant Adenovirus Vectors," Human Gene Therapy, 1 November 2002, pp. 1921-1934, Vol. 13.				
		DRITTANTI et al., "Optimised helper virus-free production of high-quality adeno-associated virus vectors," The Journal of Gene Medicine, 2001, pp. 59-71, Vol. 3.				
		SULLIVAN et al., "Development of a preventive vaccine for Ebola virus infection in primates," Nature, 30 November 2000, pp. 609-609, Vol. 408.				
	, ,					
			_			
		-				

Examiner Signature	/Benjamin Blumel/	Date Considered	02/20/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.